Comparison of intraocular pressure lowering efficacy of bimatoprost / timolol fixed combination and other glaucoma medications in the treatment of glaucoma;Srovnání fixní kombinace bimatoprostu 0,03% a timololu 0,5% s jinými kombinacemi antiglaukomatik v léčbě glaukomu

Ceska a Slovenska Oftalmologie

Volumn 64, Issue 4, 2008, Pages 144-148

  Skorkovska K ^a  

^a ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

Author keywords

Bimatoprost; Fixed combination; Glaucoma; Timolol

Indexed keywords

AMIDE; ANTIHYPERTENSIVE AGENT; BIMATOPROST; CLOPROSTENOL; DRUG DERIVATIVE; LATANOPROST; PROSTAGLANDIN F; TIMOLOL; TRAVOPROST;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; HUMAN; INTRAOCULAR HYPOTENSION; INTRAOCULAR PRESSURE; MIDDLE AGED; MULTICENTER STUDY; OPEN ANGLE GLAUCOMA; PATHOPHYSIOLOGY;

ADULT; AGED; AMIDES; ANTIHYPERTENSIVE AGENTS; CLOPROSTENOL; DRUG COMBINATIONS; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MIDDLE AGED; OCULAR HYPOTENSION; PROSTAGLANDINS F, SYNTHETIC; TIMOLOL;

EID: 53049098649     PISSN: 12119059     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol, 130, 2000: 429-440
2. Brandt, J.D., VanDenburgh, A.M., Chen, A. et al.: Comparison of once or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP. Ophthalmology, 108, 2001: 1023-1032
3. Brubaker, R.F.: Mechanism of action of bimatoprost (Lumigan). Surv Ophthalmol, 45, 2001: S347-351
4. Brubaker, R.F., Schoeff, E.O., Nau, C.B. et al.: Effects of bimatoprost, a new ocular hypotensive agent, on aqueous humor dynamics. Am J Ophthalmol, 131, 2001: 19-24
5. Camras CB.:mziill for the United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six month, masked, multicenter trial in the United States. Ophthalmology, 103, 1996: 138-147
6. Camras, C.B., Toris, C.B., Sjoquist, B. et al.: Detection of free acid of bimatoprost in aqueous humor samples from human eyes treated with bimatoprost before cataract surgery. Ophthalmology, 111, 2004: 2193-2198
7. Cantor, L.B., Hoop, J., Morgan, L. et al.: Intraocular pressure lowering efficacy of bimatoprost 0,03% and travoprost 0,004% in patients with glaucoma or ocular hypertension. Br J Ophthalmol, 90, 2006: 1370-1373
8. Christiansen, G.A., Nau, C.B., Mc Laren, J.W. et al.: Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma. Ophthalmology, 111, 2004: 1658-1662
9. nd edition. Savona, Italy: DOGMA, Srl, 2003
10. Heijl, A., Leske, M.C., Bengtsson B. et al.: Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol, 120, 2002: 1268-1279
11. Higginbotham, E.J., Schuman, J.S., Goldberg, I. et al.: Bimatoprost Study Groups 1 and 2. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol, 120, 2002: 1286-1293
12. Hommer, A. Ganfort Investigators group I. A double-masked, randomized, parallel comparison of a fixed combination use in patients with glaucoma or ocular hypertension. Eur J Ophthalmol, 17, 2007: 53-62
13. Kass, M.A., Heuer, D.K., Higginbotham, E.J. et al.: The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open/angle glaucoma. Arch Ophthalmol, 120, 2002: 701-713
14. Konstas, A.G., Hollo, G., Irkec, M. et al.: Diurnal IOP control with bimatoprost vs latanoprost in exfoliative glaucoma: a crossover observer-masked three center study. Br J Ophthalmol, 91, 2007: 757-760
15. Kulkarni P.S.: The role of endogenous eicosanoids in rabbit intraocular inflammation. J Ocular Pharmacol, 7, 1991:227-241
16. Maihöfner. C., Schloetzer-Schrehardt, U., Gühring, H. et al.: Expressions of cyclooxygenase 2 in normal and glaucomatous eyes (abstract). Invest Ophthalmol Vis Sci, 40, 1999: S827
17. Martinez, A., Sanchez, M.: A comparison of the safety and intraocular pressure lowering of bimatoprost / timolol fixed combination versus latanoprost / timolol fixed combination in patients with open-angle glaucoma. Curr Med Res Opin, 23, 2007: 1025-1032
18. Michels-Rautenstrauss, K., Mardin, C.Y., Schweitzer, D. et al.: GL-CIA-locus: mutation screening in MYOC/TIGR and COX-2 of German POAG patients (abstract). Proc Am Soc Human Genetics, 65, 2000: 2731
19. Noecker, R.S., Dirks, M.S., Choplin, N.T. et al.: Bimatoprost / Latanoprost study group. A six-month randomized clinical trial comparing the intraocular pressure - lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol, 135, 2003: 55-63
20. Ocklind, A., Lake, S., Wentzel, P. et al.: Localization of the prostaglandin F2 alpha receptor messenger RNA and protein in the cynomolgus monkey eye. Invest Ophthalmol Vis Sci, 37, 1996: 716-726
21. Parrish, R.K., Palmberg, P., Sheu, W.P. for the XLT Study Group. A comparison of latanoprost, bimatoprost and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol, 135, 2003: 688-703
22. Stewart, W.C., Holmes, K.T., Johnson, M.A.: Washout periods for brimonidine 0.2% and latanoprost 0,005%. Am J Ophthalmol, 131, 2001: 798-799
23. Stjernschutz, J.W. From PGF 2@ - isopropyl ester to latanoprost: a review of the development of Xalatan: the Proctor Lecture. Invest Ophthalmol Vis Sci, 42, 2001: 1134-1145
24. Weinreb, R.N., Toris, C.B., Gabelt, A.T. et al.: Effects of prostaglandins on the aqueous humor outflow pathways. Surv Ophthalmol, 47 (Suppl. 1), 2002: S53-S64
25. Woodward, D.F., Krauss, A.H., Wang, J.W. et al.: Identification of an antagonist that selectively blocks the activity of prostamides (prostaglandin-ethanolamides) in the feline iris. Br J Pharmacol, 150, 2007: 342-352